Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

The US Food and Drug Administration (FDA) recently approved Perrigo Company’s (PRGO - Analyst Report) Abbreviated New Drug Applications (ANDAs) to market over-the-counter nicotine polacrilex mini lozenge, 2 mg (mint flavor) and 4 mg (mint flavor). Perrigo expects to start shipping the product by year end.

Mini nicotine lozenges help to reduce withdrawal symptoms like nicotine craving, associated with quitting smoking. This is the first approval for mini lozenge products targeting the store brand market. The mint flavored mini lozenge can be compared to GlaxoSmithKline's (GSK - Analyst Report) Nicorette mini lozenge.

We note that Glaxo markets Nicorette (Original, Mint and Orange) globally. Perrigo stated in its press release that annual sales of Nicorette mini lozenge are more than $30 million at all retail outlets.

We remind investors that last month Perrigo filed an ANDA with the FDA, seeking approval for its generic version of Teva Pharmaceutical Industries Limited’s (TEVA - Analyst Report) ProAir HFA inhaler. The application included contributions from Perrigo’s partner on the project, the privately-held Catalent Pharma.

Teva is challenging Perrigo’s application, thereby initiating the litigation process under the Hatch-Waxman Act. Perrigo is the first company to seek approval for the generic version of the drug and is therefore entitled to 180 days of generic exclusivity.

We also note that the generic unit at Perrigo has seen quite a few approvals over the past few months including its generic versions of Clobex shampoo, inflammatory acne therapy Duac gel, hyperphosphatemia drug, Phoslo Gelcaps and vaginal cream Gynazole 1 for the local treatment of vulvovaginal candidiasis.

Our Recommendation

We currently have a Neutral recommendation on Perrigo. The stock carries a Zacks #3 Rank (Hold) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%